Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome
- PMID:15371516
- PMCID: PMC6729789
- DOI: 10.1523/JNEUROSCI.1766-04.2004
Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome
Abstract
Although many genetic disorders are characterized by cognitive failure during development, there is little insight into the neurobiological basis for the abnormalities. Down syndrome (DS), a disorder caused by the presence of three copies of chromosome 21 (trisomy 21), is characterized by impairments in learning and memory attributable to dysfunction of the hippocampus. We explored the cellular basis for these abnormalities in Ts65Dn mice, a genetic model for DS. Although basal synaptic transmission in the dentate gyrus was normal, there was severe impairment of long-term potentiation (LTP) as a result of reduced activation of NMDA receptors. After suppressing inhibition with picrotoxin, a GABA(A) receptor antagonist, NMDA receptor-mediated currents were normalized and induction of LTP was restored. Several lines of evidence suggest that inhibition in the Ts65Dn dentate gyrus was enhanced, at least in part, because of presynaptic abnormalities. These findings raise the possibility that similar changes contribute to abnormalities in learning and memory in people with DS and, perhaps, in other developmental disorders with cognitive failure.
Figures







Similar articles
- Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships.Belichenko PV, Kleschevnikov AM, Salehi A, Epstein CJ, Mobley WC.Belichenko PV, et al.J Comp Neurol. 2007 Oct 1;504(4):329-45. doi: 10.1002/cne.21433.J Comp Neurol. 2007.PMID:17663443
- Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.Kleschevnikov AM, Yu J, Kim J, Lysenko LV, Zeng Z, Yu YE, Mobley WC.Kleschevnikov AM, et al.Neurobiol Dis. 2017 Jul;103:1-10. doi: 10.1016/j.nbd.2017.03.009. Epub 2017 Mar 22.Neurobiol Dis. 2017.PMID:28342823Free PMC article.
- Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists.Kleschevnikov AM, Belichenko PV, Faizi M, Jacobs LF, Htun K, Shamloo M, Mobley WC.Kleschevnikov AM, et al.J Neurosci. 2012 Jul 4;32(27):9217-27. doi: 10.1523/JNEUROSCI.1673-12.2012.J Neurosci. 2012.PMID:22764230Free PMC article.
- Synaptic pathology of Down syndrome.Garner CC, Wetmore DZ.Garner CC, et al.Adv Exp Med Biol. 2012;970:451-68. doi: 10.1007/978-3-7091-0932-8_20.Adv Exp Med Biol. 2012.PMID:22351068Review.
- From abnormal hippocampal synaptic plasticity in down syndrome mouse models to cognitive disability in down syndrome.Cramer N, Galdzicki Z.Cramer N, et al.Neural Plast. 2012;2012:101542. doi: 10.1155/2012/101542. Epub 2012 Jul 12.Neural Plast. 2012.PMID:22848844Free PMC article.Review.
Cited by
- Regulation of GABAergic neurotransmission by purinergic receptors in brain physiology and disease.Juvenal G, Higa GSV, Bonfim Marques L, Tessari Zampieri T, Costa Viana FJ, Britto LR, Tang Y, Illes P, di Virgilio F, Ulrich H, de Pasquale R.Juvenal G, et al.Purinergic Signal. 2025 Feb;21(1):149-177. doi: 10.1007/s11302-024-10034-x. Epub 2024 Jul 24.Purinergic Signal. 2025.PMID:39046648Review.
- Transcriptional dysregulation causes altered modulation of inhibition by haloperidol.Brady LJ, Bartley AF, Li Q, McMeekin LJ, Hablitz JJ, Cowell RM, Dobrunz LE.Brady LJ, et al.Neuropharmacology. 2016 Dec;111:304-313. doi: 10.1016/j.neuropharm.2016.07.034. Epub 2016 Jul 29.Neuropharmacology. 2016.PMID:27480797Free PMC article.
- Trisomy 21 and early brain development.Haydar TF, Reeves RH.Haydar TF, et al.Trends Neurosci. 2012 Feb;35(2):81-91. doi: 10.1016/j.tins.2011.11.001. Epub 2011 Dec 9.Trends Neurosci. 2012.PMID:22169531Free PMC article.Review.
- Activation of the ISR mediates the behavioral and neurophysiological abnormalities in Down syndrome.Zhu PJ, Khatiwada S, Cui Y, Reineke LC, Dooling SW, Kim JJ, Li W, Walter P, Costa-Mattioli M.Zhu PJ, et al.Science. 2019 Nov 15;366(6467):843-849. doi: 10.1126/science.aaw5185.Science. 2019.PMID:31727829Free PMC article.
- Abnormal brain synchrony in Down Syndrome.Anderson JS, Nielsen JA, Ferguson MA, Burback MC, Cox ET, Dai L, Gerig G, Edgin JO, Korenberg JR.Anderson JS, et al.Neuroimage Clin. 2013 May 24;2:703-15. doi: 10.1016/j.nicl.2013.05.006. eCollection 2013.Neuroimage Clin. 2013.PMID:24179822Free PMC article.
References
- Adamec RE, McNaughton B, Racine R, Livingston KE (1981) Effects of diazepam on hippocampal excitability in the rat: action in the dentate area. Epilepsia 22: 205-215. - PubMed
- Antonarakis SE, Lyle R, Chrast R, Scott HS (2001) Differential gene expression studies to explore the molecular pathophysiology of Down syndrome. Brain Res Brain Res Rev 36: 265-274. - PubMed
- Auld DS, Kar S, Quirion R (1998) Beta-amyloid peptides as direct cholinergic neuromodulators: a missing link? Trends Neurosci 21: 43-49. - PubMed
- Aylward EH, Li Q, Honeycutt NA, Warren AC, Pulsifer MB, Barta PE, Chan MD, Smith PD, Jerram M, Pearlson GD (1999) MRI volumes of the hippocampus and amygdala in adults with Down's syndrome with and without dementia. Am J Psychiatry 156: 564-568. - PubMed
- Barnes CA (1979) Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. J Comp Physiol Psychol 93: 74-104. - PubMed
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases